| Literature DB >> 31417091 |
Ikuyo Kou1, Nao Otomo1,2, Kazuki Takeda1,2, Yukihide Momozawa3, Hsing-Fang Lu1,4, Michiaki Kubo3, Yoichiro Kamatani5,6, Yoji Ogura2, Yohei Takahashi2, Masahiro Nakajima1, Shohei Minami7, Koki Uno8, Noriaki Kawakami9, Manabu Ito10, Ikuho Yonezawa11, Kei Watanabe12, Takashi Kaito13, Haruhisa Yanagida14, Hiroshi Taneichi15, Katsumi Harimaya16, Yuki Taniguchi17, Hideki Shigematsu18, Takahiro Iida19, Satoru Demura20, Ryo Sugawara21, Nobuyuki Fujita2, Mitsuru Yagi2, Eijiro Okada2,22, Naobumi Hosogane2,23, Katsuki Kono2,24, Masaya Nakamura2, Kazuhiro Chiba2,23, Toshiaki Kotani7, Tsuyoshi Sakuma7, Tsutomu Akazawa7, Teppei Suzuki8, Kotaro Nishida25, Kenichiro Kakutani25, Taichi Tsuji9, Hideki Sudo26, Akira Iwata27, Tatsuya Sato11, Satoshi Inami15, Morio Matsumoto2, Chikashi Terao28, Kota Watanabe29, Shiro Ikegawa30.
Abstract
Adolescent idiopathic scoliosis (AIS) is the most common pediatric spinal deformity. Several AIS susceptibility loci have been identified; however, they could explain only a small proportion of AIS heritability. To identify additional AIS susceptibility loci, we conduct a meta-analysis of the three genome-wide association studies consisting of 79,211 Japanese individuals. We identify 20 loci significantly associated with AIS, including 14 previously not reported loci. These loci explain 4.6% of the phenotypic variance of AIS. We find 21 cis-expression quantitative trait loci-associated genes in seven of the fourteen loci. By a female meta-analysis, we identify additional three significant loci. We also find significant genetic correlations of AIS with body mass index and uric acid. The cell-type specificity analyses show the significant heritability enrichment for AIS in multiple cell-type groups, suggesting the heterogeneity of etiology and pathogenesis of AIS. Our findings provide insights into etiology and pathogenesis of AIS.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31417091 PMCID: PMC6695451 DOI: 10.1038/s41467-019-11596-w
Source DB: PubMed Journal: Nat Commun ISSN: 2041-1723 Impact factor: 14.919
Association of the genome-wide significant loci
| SNP | Chr. | Pos. | Gene in or near Region of association | RA | RAF Case | RAF Control | OR | 95% CI |
| Genotyped/imputation | Min Rsq | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Previously unreported loci | ||||||||||||
| rs141903557 | 4q21.23 | 85168056 | LOC101928978 | C | 0.060 | 0.047 | 9.78 × 10−11 | 1.33 | 1.22-1.45 | 0.52 | Imputed | 0.98 |
| rs11205303 | 1q21.2 | 149906413 | MTMR11 | C | 0.24 | 0.21 | 1.62 × 10−10 | 1.17 | 1.11-1.23 | 0.91 | Genotyped | 0.94 |
| rs12029076 | 1q42.13 | 228272687 | ARF1 | G | 0.81 | 0.78 | 2.17 × 10−10 | 1.18 | 1.12-1.24 | 0.40 | Imputed | 0.99 |
| rs1978060 | 22q11.21 | 19749525 | TBX1 | G | 0.49 | 0.47 | 3.26 × 10−10 | 1.16 | 1.11-1.22 | 0.62 | Imputed | 0.72 |
| rs2467146 | 12p12.3 | 17800607 | LINC02378/MIR3974 | A | 0.70 | 0.67 | 5.96 × 10−10 | 1.15 | 1.10-1.20 | 0.23 | Imputed | 0.99 |
| rs11787412 | 8p23.2 | 3134239 | CSMD1 | A | 0.42 | 0.38 | 1.32 × 10−9 | 1.14 | 1.09-1.18 | 0.86 | Imputed | 0.99 |
| rs188915802 | 9p13.3 | 34318683 | KIF24 | T | 0.019 | 0.013 | 1.94 × 10−9 | 1.66 | 1.41-1.96 | 0.05 | Imputed | 0.81 |
| rs658839 | 6q14.1 | 81228722 | BCKDHB/FAM46A | G | 0.54 | 0.51 | 3.15 × 10−9 | 1.14 | 1.09-1.19 | 0.88 | Imputed | 0.85 |
| rs160335 | 7p15.1 | 28587817 | CREB5 | G | 0.54 | 0.51 | 9.10 × 10−9 | 1.13 | 1.08-1.18 | 0.69 | Imputed | 0.96 |
| rs482012 | 6q22.1 | 116430533 | NT5DC1 | T | 0.74 | 0.72 | 2.30 × 10−8 | 1.14 | 1.09-1.19 | 0.15 | Genotyped | 0.99 |
| rs11341092 | 7p22.3 | 1269592 | LOC101927021/UNCX | AC | 0.33 | 0.31 | 2.92 × 10−8 | 1.14 | 1.09-1.19 | 0.93 | Imputed | 0.81 |
| rs17011903 | 1q32.2 | 208259531 | PLXNA2 | A | 0.11 | 0.10 | 3.56 × 10−8 | 1.20 | 1.13-1.28 | 0.11 | Imputed | 0.98 |
| rs397948882 | 7p21.2 | 15636869 | AGMO/MEOX2 | A | 0.11 | 0.10 | 3.66 × 10−8 | 1.20 | 1.12-1.28 | 0.72 | Imputed | 0.98 |
| rs12149832 | 16q12.2 | 53842908 | FTO | G | 0.82 | 0.79 | 4.40 × 10−8 | 1.16 | 1.10-1.22 | 0.34 | Genotyped | 0.96 |
| Previously reported loci | ||||||||||||
| rs11190870 | 10q24.31 | 102979207 | LINC01514/LBX1 | T | 0.66 | 0.56 | 2.01 × 10−82 | 1.52 | 1.46-1.59 | 0.22 | Genotyped | 1 |
| rs9389985 | 6q24.1 | 142653898 | ADGRG6 | G | 0.48 | 0.43 | 3.51 × 10−20 | 1.21 | 1.16-1.26 | 0.43 | Imputed | 0.96 |
| rs7028900 | 9p22.2 | 16690612 | BNC2 | C | 0.46 | 0.42 | 2.19 × 10−17 | 1.20 | 1.15-1.25 | 0.93 | Imputed | 0.93 |
| rs144131194 | 9q34.2 | 136145993 | ABO | AAGAAGGGAAATTAATAAATATT | 0.58 | 0.55 | 1.35 × 10−11 | 1.15 | 1.11-1.20 | 0.96 | Imputed | 1 |
| rs6047716 | 20p11.22 | 21894005 | PAX1/LINC01432 | C | 0.51 | 0.47 | 1.45 × 10−11 | 1.15 | 1.11-1.20 | 0.77 | Imputed | 0.97 |
| rs2194285 | 16q23.3 | 82894817 | CDH13 | G | 0.13 | 0.11 | 8.69 × 10−9 | 1.19 | 1.12-1.27 | 0.80 | Genotyped | 1 |
Chr. chromosome, Pos. genomic position (GRCh37/hg19), RA risk allele, RAF risk allele frequency, OR odds ratio, CI confidence interval, Phet P values for heterogeneity from Cochran’s Q-test
aThe combined P values were calculated by the inverse-variance method under a fixed-effect model
Fig. 1Manhattan plot showing the –log10 P value for the SNPs in the AIS GWAS. P values were derived from the meta-analysis by using the inverse-variance method under a fixed-effect model. The red line represents the genome-wide significance threshold (P = 5 × 10−8). The genetic loci that satisfied the genome-wide significance threshold in the meta-analysis of the three GWAS are labeled
Fig. 2Relationship between effect size and minor allele frequency. The meta-analysis effect size (y axis) and the minor allele frequency (x axis) for 20 significant SNPs. Red circles represent the SNPs at previously unreported loci (n = 14) and blue circles represent the SNPs at previously reported loci (n = 6). Effect sizes are measured as odds ratios, which give the odds of the outcome given exposure to one risk allele compared with those to no risk allele
Association of the genome-wide significant loci for female AIS (only loci FEMALE-sig)
| SNP | Chr. | Pos. | Gene in or near region of association | RA | F_RAF Case | F_RAF Control | F_OR (95% CI) | F_ | M_RAF Case | M_RAF Control | M_OR (95% CI) | M_ |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| rs73235136 | 3q13.2 | 112951529 | BOC | C | 0.50 | 0.46 | 1.15 (1.10–1.20) | 3.45 × 10−9 | 0.44 | 0.47 | 0.88 (0.75–1.03) | 1.01 × 10−1 | 0.00057 |
| rs545608 | 1q25.2 | 177899121 | SEC16B | G | 0.76 | 0.73 | 1.16 (1.10–1.23) | 1.03 × 10−8 | 0.75 | 0.74 | 1.05 (0.88–1.25) | 6.15 × 10−1 | 0.13 |
| rs142502288 | 1q23.3 | 162450931 | SH2D1B/UHMK1 | G | 0.028 | 0.020 | 1.52 (1.31–1.76) | 3.11 × 10−8 | 0.025 | 0.023 | 1.10 (0.66–1.84) | 7.13 × 10−1 | 0.88 |
Chr. chromosome, Pos. genomic position (GRCh37/hg19), F female, M male, RA risk allele, RAF risk allele frequency, OR odds ratio, CI confidence interval, Phet P values for heterogeneity from Cochran’s Q-test
aThe combined P values were calculated by the inverse-variance method under a fixed-effect model
Fig. 3Allelic difference of functional variant, rs1978060 in Chr.22q11.21. a Reporter assays in MCF-7 cells. There was a significantly decreased transcriptional activity for the risk G-allele of rs1978060 compared to the non-risk A-allele. Error bars show standard deviation (S.D.) for each variant. Asterisks indicate statistically significant changes in paired comparison (t-test P < 0.01). n = 2 independent experiments. b Electrophoretic mobility shift assays with nuclear extracts from MCF-7 cells. There was specific bands for A-allele probe (lane 1, black arrow) and the G-allele probe (lane 2, white arrow) of rs1978060. Competition analyses were performed using an excess of the unlabeled A-allele probe (lane 3, lane 6) and G-allele probe (lane 4, lane 5) as competitors. c A super-shift assay using the FOXA2 antibody. The black arrow indicates a super-shifted FOXA2 complex in lane 3. Source data are provided as a Source Data file